These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 23470153

  • 1. High response rate to low-dose rituximab plus high-dose dexamethasone as frontline therapy in adult patients with primary immune thrombocytopenia.
    Gómez-Almaguer D, Tarín-Arzaga L, Moreno-Jaime B, Jaime-Pérez JC, Ceballos-López AA, Ruiz-Argüelles GJ, Ruiz-Delgado GJ, Cantú-Rodríguez OG, Gutiérrez-Aguirre CH, Sánchez-Cárdenas M.
    Eur J Haematol; 2013 Jun; 90(6):494-500. PubMed ID: 23470153
    [Abstract] [Full Text] [Related]

  • 2. Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia.
    Zaja F, Volpetti S, Chiozzotto M, Puglisi S, Isola M, Buttignol S, Fanin R.
    Am J Hematol; 2012 Sep; 87(9):886-9. PubMed ID: 22718483
    [Abstract] [Full Text] [Related]

  • 3. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone.
    Cheng Y, Wong RS, Soo YO, Chui CH, Lau FY, Chan NP, Wong WS, Cheng G.
    N Engl J Med; 2003 Aug 28; 349(9):831-6. PubMed ID: 12944568
    [Abstract] [Full Text] [Related]

  • 4. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial.
    Ghanima W, Khelif A, Waage A, Michel M, Tjønnfjord GE, Romdhan NB, Kahrs J, Darne B, Holme PA, RITP study group.
    Lancet; 2015 Apr 25; 385(9978):1653-61. PubMed ID: 25662413
    [Abstract] [Full Text] [Related]

  • 5. Low-dose rituximab in adult patients with primary immune thrombocytopenia.
    Zaja F, Vianelli N, Volpetti S, Battista ML, Defina M, Palmieri S, Bocchia M, Medeot M, De Luca S, Ferrara F, Isola M, Baccarani M, Fanin R.
    Eur J Haematol; 2010 Oct 25; 85(4):329-34. PubMed ID: 20546023
    [Abstract] [Full Text] [Related]

  • 6. [The efficacy and safety of 2 cycles' high-dose dexamethasone treatment adult primary immune thrombocytopenia].
    Cui ZG, Wei Y, Hou M, Zhao HG, Wang HY.
    Zhonghua Nei Ke Za Zhi; 2011 May 25; 50(5):401-3. PubMed ID: 21624223
    [Abstract] [Full Text] [Related]

  • 7. A multi-centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study).
    Tran H, Brighton T, Grigg A, McRae S, Dixon J, Thurley D, Gandhi MK, Truman M, Marlton P, Catalano J.
    Br J Haematol; 2014 Oct 25; 167(2):243-51. PubMed ID: 25041261
    [Abstract] [Full Text] [Related]

  • 8. [Clinical study of standard dose of rituximab for the treatment of refractory primary immune thrombocytopenia].
    Zhu YC, Wang W, Zhou YH, Wang XM, Wang X, Wang YL, Sun GZ, Hou M.
    Zhonghua Xue Ye Xue Za Zhi; 2011 Mar 25; 32(3):163-7. PubMed ID: 21535953
    [Abstract] [Full Text] [Related]

  • 9. [Combination therapy of thymosin alpha1 and high dose dexamethasone in patients with chronic idiopathic thrombocytopenic purpura].
    Wang L, Guo CS, Hou M, Li LZ, Zhang CQ, Chen F, Qin P, Peng J, He WD, Chu XX.
    Zhonghua Nei Ke Za Zhi; 2007 Apr 25; 46(4):274-6. PubMed ID: 17637261
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of rituximab given at 1,000 mg on days 1 and 15 compared to the standard regimen to treat adult immune thrombocytopenia.
    Mahévas M, Ebbo M, Audia S, Bonnotte B, Schleinitz N, Durand JM, Chiche L, Khellaf M, Bierling P, Roudot-Thoraval F, Godeau B, Michel M.
    Am J Hematol; 2013 Oct 25; 88(10):858-61. PubMed ID: 23798363
    [Abstract] [Full Text] [Related]

  • 11. Chronic lymphocytic leukemia-associated immune thrombocytopenia treated with rituximab: a retrospective study of 21 patients.
    D'Arena G, Capalbo S, Laurenti L, Del Poeta G, Nunziata G, Deaglio S, Spinosa G, Tarnani M, De Padua L, Califano C, Ferrara F, Cascavilla N.
    Eur J Haematol; 2010 Dec 25; 85(6):502-7. PubMed ID: 20846302
    [Abstract] [Full Text] [Related]

  • 12. Therapy with rituximab for autoimmune pemphigus: results from a single-center observational study on 42 cases with long-term follow-up.
    Cianchini G, Lupi F, Masini C, Corona R, Puddu P, De Pità O.
    J Am Acad Dermatol; 2012 Oct 25; 67(4):617-22. PubMed ID: 22243765
    [Abstract] [Full Text] [Related]

  • 13. Effect of high-dose dexamethasone in prednisone-resistant autoimmune thrombocytopenic purpura (ITP).
    Dubbeld P, van der Heul C, Hillen HF.
    Neth J Med; 1991 Aug 25; 39(1-2):6-10. PubMed ID: 1961352
    [Abstract] [Full Text] [Related]

  • 14. Low-dose rituximab combined with short-term glucocorticoids up-regulates Treg cell levels in patients with immune thrombocytopenia.
    Li Z, Mou W, Lu G, Cao J, He X, Pan X, Xu K.
    Int J Hematol; 2011 Jan 25; 93(1):91-8. PubMed ID: 21188563
    [Abstract] [Full Text] [Related]

  • 15. Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab.
    Schweizer C, Reu FJ, Ho AD, Hensel M.
    Ann Hematol; 2007 Oct 25; 86(10):711-7. PubMed ID: 17622529
    [Abstract] [Full Text] [Related]

  • 16. Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura.
    Zaja F, Battista ML, Pirrotta MT, Palmieri S, Montagna M, Vianelli N, Marin L, Cavallin M, Bocchia M, Defina M, Ippoliti M, Ferrara F, Patriarca F, Avanzini MA, Regazzi M, Baccarani M, Isola M, Soldano F, Fanin R.
    Haematologica; 2008 Jun 25; 93(6):930-3. PubMed ID: 18403395
    [Abstract] [Full Text] [Related]

  • 17. Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia.
    Gudbrandsdottir S, Birgens HS, Frederiksen H, Jensen BA, Jensen MK, Kjeldsen L, Klausen TW, Larsen H, Mourits-Andersen HT, Nielsen CH, Nielsen OJ, Plesner T, Pulczynski S, Rasmussen IH, Rønnov-Jessen D, Hasselbalch HC.
    Blood; 2013 Mar 14; 121(11):1976-81. PubMed ID: 23293082
    [Abstract] [Full Text] [Related]

  • 18. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis.
    Smith RM, Jones RB, Guerry MJ, Laurino S, Catapano F, Chaudhry A, Smith KG, Jayne DR.
    Arthritis Rheum; 2012 Nov 14; 64(11):3760-9. PubMed ID: 22729997
    [Abstract] [Full Text] [Related]

  • 19. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
    Braendstrup P, Bjerrum OW, Nielsen OJ, Jensen BA, Clausen NT, Hansen PB, Andersen I, Schmidt K, Andersen TM, Peterslund NA, Birgens HS, Plesner T, Pedersen BB, Hasselbalch HC.
    Am J Hematol; 2005 Apr 14; 78(4):275-80. PubMed ID: 15795920
    [Abstract] [Full Text] [Related]

  • 20. Treatment of Children with Persistent and Chronic Idiopathic Thrombocytopenic Purpura: 4 Infusions of Rituximab and Three 4-Day Cycles of Dexamethasone.
    Oved JH, Lee CSY, Bussel JB.
    J Pediatr; 2017 Dec 14; 191():225-231. PubMed ID: 29173312
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.